News

Biofortuna closes £1.6M funding round

Biofortuna Ltd, a UK-based diagnostics company offering molecular diagnostic products and contract manufacturing services, has raised £1.6M in its latest funding round. The new funding –supported by current investor Foresight VCTs and members of the senior management team – will allow the company to take its ReadyPlex™ rapid blood group genotyping assays into clinical trials and commercialisation, as well as invest in additional resources in its contract manufacturing infrastructure.

Tuesday, August 15, 2017
READ MORE   

Biofortuna expands its immunoassay development and manufacturing services

Biofortuna is expanding its IVD service portfolio to provide a greater focus on immunoassay design, development and manufacture. The company has made a significant investment in its production capabilities to include plate coating, washing, drying and quality control, creating an exceptional manufacturing suite for immunoassay kits.

Tuesday, January 24, 2017
READ MORE   

Biofortuna reaches key milestones for ReadyPlex™ blood group genotyping product family

Biofortuna Ltd, a UK-based diagnostics company offering molecular diagnostic products and contract manufacturing services, has successfully achieved key milestones in the development of its new blood group genotyping product family – ReadyPlex™.

Monday, October 3, 2016
READ MORE   

Biofortuna FDA Inspection Completed Successfully

Biofortuna have successfully completed an FDA site inspection to retain their FDA registered manufacturing site status.

Friday, July 8, 2016
READ MORE   

Record year for Biofortuna Contract Services division

Biofortuna Ltd is pleased to announce a record year of growth for its IVD Contract Services division. This growth has been driven by the expansion of its service portfolio, together with increased demand for its core lyophilisation services.

Wednesday, May 18, 2016
READ MORE   

| Next Page